Switch theme
Sign up to access all valuation multiples
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
1990
229
LTM Revenue $123M
LTM EBITDA n/a
$556M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Geron has a last 12-month revenue of $123M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Geron achieved revenue of $77.0M and an EBITDA of -$155M.
Geron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Geron valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $77.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$175M | -$155M | XXX | XXX | XXX |
| EBITDA Margin | -73748% | -201% | XXX | XXX | XXX |
| Net Profit | -$142M | -$184M | XXX | XXX | XXX |
| Net Margin | -59874% | -239% | XXX | XXX | XXX |
| Net Debt | n/a | $11.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Geron's stock price is $1.
Geron has current market cap of $841M, and EV of $556M.
See Geron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $556M | $841M | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Geron has market cap of $841M and EV of $556M.
Geron's trades at 4.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Geron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Geron and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $556M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.6x | XXX | XXX | XXX |
| P/E | -4.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGeron's NTM/LTM revenue growth is 126%
Geron's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Geron's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Geron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Geron and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 32387% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -201% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -75% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 189% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 135% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 324% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Geron acquired XXX companies to date.
Last acquisition by Geron was XXXXXXXX, XXXXX XXXXX XXXXXX . Geron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Geron founded? | Geron was founded in 1990. |
| Where is Geron headquartered? | Geron is headquartered in United States of America. |
| How many employees does Geron have? | As of today, Geron has 229 employees. |
| Who is the CEO of Geron? | Geron's CEO is Ms. Dawn Carter Bir. |
| Is Geron publicy listed? | Yes, Geron is a public company listed on NAS. |
| What is the stock symbol of Geron? | Geron trades under GERN ticker. |
| When did Geron go public? | Geron went public in 1996. |
| Who are competitors of Geron? | Similar companies to Geron include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Geron? | Geron's current market cap is $841M |
| What is the current revenue of Geron? | Geron's last 12-month revenue is $123M. |
| What is the current EV/Revenue multiple of Geron? | Current revenue multiple of Geron is 4.5x. |
| What is the current revenue growth of Geron? | Geron revenue growth between 2023 and 2024 was 32387%. |
| Is Geron profitable? | Yes, Geron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
